Neurocrine Biosciences Inc (NBIX) is a publicly traded Healthcare sector company. As of October 20, 2026, NBIX trades at $140.13 with a market cap of $13.79B and a P/E ratio of 20.22. NBIX moved +1.80% today. Year to date, NBIX is -2.57%; over the trailing twelve months it is -2.22%. Its 52-week range spans $84.23 to $186.12. Analyst consensus is strong buy with an average price target of $207.28. Rallies surfaces NBIX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
26 analysts cover NBIX: 0 strong buy, 23 buy, 3 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $207.28.
| Metric | Value |
|---|---|
| Price | $140.13 |
| Market Cap | $13.79B |
| P/E Ratio | 20.22 |
| EPS | $7.05 |
| Dividend Yield | 0.00% |
| 52-Week High | $186.12 |
| 52-Week Low | $84.23 |
| Volume | 152.73K |
| Avg Volume | 0 |
| Revenue (TTM) | $3.37B |
| Net Income | $705.50M |
| Gross Margin | 0.00% |
26 analysts cover NBIX: 0 strong buy, 23 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $207.28.